Acomplia diet drug

NEW YORK (AP) — An HSBC analyst upgraded Sanofi-Aventis SA Wednesday, citing the French drug maker’s full pipeline and shrugging off its failure to receive U.S. approval for the weight-loss drug rimonabant study.

In late June, Sanofi-Aventis withdrew its application to gain U.S. approval for rimonabant study, following a meeting in which government advisers rejected the treatment on safety grounds. The Paris-based company said it would resubmit its Food and Drug Administration application for rimonabant study at a later date.Despite the rimonabant issues, HSBC analyst Kevin Scotcher on Wednesday raised his rating on Sanofi shares to “Overweight” or “Buy” from “Neutral,” citing the company’s new drug portfolio.”Given the share price decline post the failure to commercialise rimonabant in the U.S. in 2007, we nonetheless point out that Sanofi has numerically the fullest pipeline among the 11 U.S. and European drug majors under our coverage,” Scotcher wrote in a note to investors.HSBC did lower its price target on the shares to 71 euros ($98) from 72.50 euros, however. The analyst pointed to risks including the possibility that Sanofi could launch a highly leveraged takeover of American rival Bristol-Myers Squibb Co.The uncertain future for rimonabant weight loss raises pressure on the French drug maker to make acquisitions to boost its drug portfolio, analysts have said.Scotcher said generic versions of Plavix, which is Bristol-Myers Squibb Co.’s best selling product, could enter the market before patent expiration. Sanofi-Aventis sells Plavix in the United States through Bristol-Myers.Shares of Sanofi-Aventis fell 26 cents to $42.45 in afternoon trading on below-average volume. Shares of Bristol-Myers fell 31 cents to $31.84 in afternoon trading, but earlier in the day hit a 52-week high of $32.35.

Anti-obesity drugs are the prime requirement of millions of obese across the world. Only an obese knows well about the problem related with obesity. Every third person tries to instruct an obese what to eat and what not to. There are people who laugh at an obese. Every obese knows that obesity can be cured with the help of suppression of appetite and proper exercising. Both things are easy to suggest but difficult to do. Exercising needs time and where is the time in the busy schedule to do rigorous exercising? How can an obese suppress appetite when urge for food is acute?

Appetite can be effectively suppressed with the aid of appetite suppressing drugs(rimonabant weight loss). The list of such drugs is long but most of them are in the weight loss drug market for years and obesity is still there. This puts a big question mark on the efficacy of those appetite suppressants. Recently, Sanofi-Aventis a drug manufacturing company of France has launched a new medication in the European anti-obesity drug market.This drug is introduced by name of rimonabant weight loss and was initially launched in the UK drug market where countless obese found it very effective. rimonabant weight loss is a product of advance drug development technology whose line action of is quiet different from almost all anti-obesity medication available in the market. Cells of our body have neurotic receptors named as cannaboid receptor-1; this receptor is responsible for the transmission of hunger signal to the brain. The substance, which can block the working of CB-1 receptor, can be a proven appetite suppressant. 2006 rimonabant’s active ingredient Rimonabant 2006 does this work. rimonabant can also help in the cessation of smoking by inhibiting the working of the CB-1 receptor. Tags:rimonabant 2006,[rimonabant study],(rimonabant weight loss)